Trieste, May 27^th 2024 - Ulisse Biomed SpA, an Italian healthcare biotech company active in the diagnostics, theranostics and therapeutic fields, and Elettrobiochimica Srl, a company active in the field of laboratory diagnostics for the study, construction and supply of analysis laboratories aimed at clinical pathology, microbiology, virology, genetics and oncological diagnosis, have signed a service agreement to support the development of an in vitro diagnostic medical device (IVDR).

The Agreement provides for UBM to carry out activities such as the evaluation of analytical performance and the production of an IVDR Electrobiochemistry device which, downstream of the aforementioned activities, will be carried out in the clinical validation phase.

The activities envisaged by the Agreement will be performed at the R&D and production facility of Hyris, a wholly-owned subsidiary of UBM after the reverse takeover transaction announced last December 2023.

The Agreement is in addition to the one already signed in January 2024 for the same services related to another in vitro diagnostic medical device (IVDR).

"This further agreement between Elettrobiochimica and UBM confirms the strategic direction of this partnership, which began at the beginning of this year and is continuing profitably," says Stefano Occhiodoro, Owner and Managing Director of Elettrobiochimica. "Our team and UBM's team have already shown strong synergies and we are convinced that we will derive a tangible benefit from this collaboration," adds Occhiodoro.

"We are honoured to be able to support Elettrobiochimica in this path of development, validation and production of their IVDR products. Elettrobiochimica is a leading Italian company with more than 50 years of experience in the marketing of in-vitro diagnostic devices. Being able to contribute to their project consolidates confidence in our services and platform solutions," says Nicola Basile, CEO of Ulisse Biomed SpA. "The services of this agreement will be guaranteed in Hyris' R&D and production facility, demonstrating how the integration of Hyris into the UBM Group strengthens our strategic positioning and allows mutual value generation," concludes Basile.

This agreement was facilitated by BBA - Bespoke Biotech Advisory, a strategic consulting boutique in the Life Sciences sector.